Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Sep;86(3):472-473.
doi: 10.1002/ana.25536. Epub 2019 Jul 12.

Reply to "Silent Progression or Bout Onset Progressive Multiple Sclerosis?"

Bruce A C Cree  1 , Stephen L Hauser  1
Affiliations
Free article
Comment

Reply to "Silent Progression or Bout Onset Progressive Multiple Sclerosis?"

Bruce A C Cree et al. Ann Neurol. 2019 Sep.
Free article
No abstract available

PubMed Disclaimer

Comment on

  • Silent progression in disease activity-free relapsing multiple sclerosis.
    University of California, San Francisco MS-EPIC Team; Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao C, Gomez R, Ragan NR, Rush GQ, Barba P, Santaniello A, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL. University of California, San Francisco MS-EPIC Team, et al. Ann Neurol. 2019 May;85(5):653-666. doi: 10.1002/ana.25463. Epub 2019 Mar 30. Ann Neurol. 2019. PMID: 30851128 Free PMC article.
  • Silent Progression or Bout Onset Progressive Multiple Sclerosis?
    Gil-Perotin S, Alcalá C, Pérez-Miralles FC, Casanova B. Gil-Perotin S, et al. Ann Neurol. 2019 Sep;86(3):472. doi: 10.1002/ana.25537. Epub 2019 Jul 12. Ann Neurol. 2019. PMID: 31251817 No abstract available.

References

    1. Kappos L, Wolinsky JS, Giovannoni G, et al. Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. P654. Paper presented at: ECTRIMS 2017; October 25-28, 2017; Paris, France.
    1. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263-1273.
    1. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209-220.